A Study of L-735,524 in HIV-Positive Children and Adolescents

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following symptoms or conditions are excluded:
• •Significant hepatic disease including HBsAg or hepatitis C positivity.
• •Significant neurologic disease such as loss of intellectual ability, motor deficits, or seizure disorder.
• •Significant cardiac disease including dysrhythmia or cardiomyopathy.
• •Significant medical condition or laboratory abnormality that may pose additional risk to patient on study or confound the results.
• •Has a social situation that may interfere with study participation.
• •Concurrent Medication:
• •Excluded:
• •Oral contraceptives.
• •Patients with the following prior conditions are excluded:
• •History of serious allergic drug reactions.
• •History of significant cardiac disease.
• •Participation on another clinical trial within the past 4 weeks.
• •Donated blood within the past 4 weeks.
• •Prior Medication:
• •Excluded within the past 4 weeks:
• •Hematopoietic growth factors.
• •Excluded within the past 2 weeks:
• •Antiretroviral agent other than zidovudine.
• •Oral contraceptives.
• •Prophylaxis for opportunistic infections, other than aerosolized pentamidine, topical antifungals, and TMP/SMX.
• •Any other medication unless approved by Merck clinical monitor. Current illicit drug use.